155 related articles for article (PubMed ID: 17877547)
1. High-cell-passage canine coronavirus vaccine providing sterilising immunity.
Pratelli A
J Small Anim Pract; 2007 Oct; 48(10):574-8. PubMed ID: 17877547
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a modified-live canine coronavirus vaccine in dogs.
Pratelli A; Tinelli A; Decaro N; Martella V; Camero M; Tempesta M; Martini M; Carmichael LE; Buonavoglia C
Vet Microbiol; 2004 Mar; 99(1):43-9. PubMed ID: 15019110
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus.
Decaro N; Mari V; Sciarretta R; Colao V; Losurdo M; Catella C; Elia G; Martella V; Del Giudice G; Buonavoglia C
Vaccine; 2011 Mar; 29(11):2018-23. PubMed ID: 21272607
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of an inactivated canine coronavirus vaccine in pups.
Pratelli A; Tinelli A; Decaro N; Cirone F; Elia G; Roperto S; Tempesta M; Buonavoglia C
New Microbiol; 2003 Apr; 26(2):151-5. PubMed ID: 12737196
[TBL] [Abstract][Full Text] [Related]
5. Fecal immunoglobulin A antibodies in dogs infected or vaccinated with canine coronavirus.
Decaro N; Pratelli A; Tinelli A; Martella V; Camero M; Buonavoglia D; Tempesta M; Caroli AM; Buonavoglia C
Clin Diagn Lab Immunol; 2004 Jan; 11(1):102-5. PubMed ID: 14715553
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of an inactivated vaccine against clinical disease caused by canine coronavirus.
Fulker R; Wasmoen T; Atchison R; Chu HJ; Acree W
Adv Exp Med Biol; 1995; 380():229-34. PubMed ID: 8830484
[TBL] [Abstract][Full Text] [Related]
7. Immunity after natural exposure to enteric canine coronavirus does not provide complete protection against infection with the new pantropic CB/05 strain.
Decaro N; Elia G; Martella V; Campolo M; Mari V; Desario C; Lucente MS; Lorusso E; Kanellos T; Gibbons RH; Buonavoglia C
Vaccine; 2010 Jan; 28(3):724-9. PubMed ID: 19887130
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c.
Siedek EM; Schmidt H; Sture GH; Raue R
Berl Munch Tierarztl Wochenschr; 2011; 124(1-2):58-64. PubMed ID: 21306055
[TBL] [Abstract][Full Text] [Related]
9. Serological prevalence of canine respiratory coronavirus.
Priestnall SL; Brownlie J; Dubovi EJ; Erles K
Vet Microbiol; 2006 Jun; 115(1-3):43-53. PubMed ID: 16551493
[TBL] [Abstract][Full Text] [Related]
10. A serological survey of canine respiratory coronavirus in New Zealand.
More GD; Dunowska M; Acke E; Cave NJ
N Z Vet J; 2020 Jan; 68(1):54-59. PubMed ID: 31513753
[No Abstract] [Full Text] [Related]
11. Genetic evolution of canine coronavirus and recent advances in prophylaxis.
Pratelli A
Vet Res; 2006; 37(2):191-200. PubMed ID: 16472519
[TBL] [Abstract][Full Text] [Related]
12. Experimental infection of dogs with a novel strain of canine coronavirus causing systemic disease and lymphopenia.
Decaro N; Campolo M; Lorusso A; Desario C; Mari V; Colaianni ML; Elia G; Martella V; Buonavoglia C
Vet Microbiol; 2008 Apr; 128(3-4):253-60. PubMed ID: 18031959
[TBL] [Abstract][Full Text] [Related]
13. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus.
Gore TC; Lakshmanan N; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
Vet Ther; 2005; 6(1):5-14. PubMed ID: 15906266
[TBL] [Abstract][Full Text] [Related]
14. Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough).
Kontor EJ; Wegrzyn RJ; Goodnow RA
Am J Vet Res; 1981 Oct; 42(10):1694-8. PubMed ID: 6275747
[TBL] [Abstract][Full Text] [Related]
15. Three-year rabies duration of immunity in dogs following vaccination with a core combination vaccine against canine distemper virus, canine adenovirus type-1, canine parvovirus, and rabies virus.
Lakshmanan N; Gore TC; Duncan KL; Coyne MJ; Lum MA; Sterner FJ
Vet Ther; 2006; 7(3):223-31. PubMed ID: 17039445
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of canine coronavirus antibodies by an enzyme-linked immunosorbent assay in dogs in the south of Italy.
Pratelli A; Elia G; Martella V; Palmieri A; Cirone F; Tinelli A; Corrente M; Buonavoglia C
J Virol Methods; 2002 Apr; 102(1-2):67-71. PubMed ID: 11879694
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of dogs with Duramune DAPPi+LC protects against pathogenic canine parvovirus type 2c challenge.
Wilson S; Stirling C; Borowski S; Thomas A; King V; Salt J
Vet Rec; 2013 Jun; 172(25):662. PubMed ID: 23748583
[TBL] [Abstract][Full Text] [Related]
18. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus.
Spibey N; Greenwood NM; Sutton D; Chalmers WS; Tarpey I
Vet Microbiol; 2008 Apr; 128(1-2):48-55. PubMed ID: 18006253
[TBL] [Abstract][Full Text] [Related]
19. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs.
Freisl M; Speck S; Truyen U; Reese S; Proksch AL; Hartmann K
Vet J; 2017 Jan; 219():15-21. PubMed ID: 28093104
[TBL] [Abstract][Full Text] [Related]
20. The recent availability in Australia of a vaccine to protect dogs against both coronavirus and Leptospira icterohaemorrhagiae.
Zwijnenberg R
Aust Vet J; 2003 Dec; 81(12):731. PubMed ID: 15080481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
